Please use this identifier to cite or link to this item: http://hdl.handle.net/1942/43203
Full metadata record
DC FieldValueLanguage
dc.contributor.authorGeukens, T-
dc.contributor.authorBrandao, M-
dc.contributor.authorLaenen, A-
dc.contributor.authorCollignon, J-
dc.contributor.authorVan Marcke, C-
dc.contributor.authorLouviaux, I-
dc.contributor.authorDemey, W-
dc.contributor.authorVan Wambeke, S-
dc.contributor.authorSchrijvers, D-
dc.contributor.authorLecomte, S-
dc.contributor.authorMEBIS, Jeroen-
dc.contributor.authorFontaine, C-
dc.contributor.authorRutten , A-
dc.contributor.authorLybaert, W-
dc.contributor.authorAspeslagh, S-
dc.contributor.authorGoeminne, JC-
dc.contributor.authorVan Den Bulck, H-
dc.contributor.authorSeront, E-
dc.contributor.authorDe Backer, L-
dc.contributor.authorDe Roock, W-
dc.contributor.authorIgnatiadis, M-
dc.contributor.authorPrenen, H-
dc.contributor.authorVan Beckhoven, D-
dc.contributor.authorHeijlen, M-
dc.contributor.authorVerheezen, J-
dc.contributor.authorRottey, S-
dc.contributor.authorPunie, K-
dc.contributor.authorde Azambuja, E-
dc.date.accessioned2024-06-18T11:59:49Z-
dc.date.available2024-06-18T11:59:49Z-
dc.date.issued2022-
dc.date.submitted2024-06-18T11:56:57Z-
dc.identifier.citationESMO open, 7 (6) (Art N° 100610)-
dc.identifier.issn2059-7029-
dc.identifier.urihttp://hdl.handle.net/1942/43203-
dc.description.abstractSolid cancer is an independent prognostic factor for poor outcome with COVID-19. As guidelines for patient management in that setting depend on retrospective efforts, we here present the first analyses of a nationwide database of patients with cancer hospitalized with COVID-19 in Belgium, with a focus on changes in anticancer treatment plans at the time of SARS-CoV-2 infection.-
dc.description.sponsorshipFUNDING This work was supported by Pfizer, Bristol Myers SquibbCompany (BMS), Roche, Amgen, Astellas Pharma, Eli Lilly and Company, Novartis, Pierre Fabre and Leo Pharma (no grant numbers). ACKNOWLEDGEMENTS The authors acknowledge all participating institutions and their ethics committees; all health care professionals who completed the information in the central electronic case report form; the Belgian Society of Medical Oncology Executive Board for their full support of this research; and the Belgian National Health Institution Sciensano for providing the required data back to the institutions. This study was an investigator-initiated trial conducted by the Belgian Society of Medical Oncology as legal sponsor, independently of the funding sources.-
dc.language.isoen-
dc.publisherELSEVIERRADARWEG 29-
dc.rights2022 The Authors. Published by Elsevier Ltd on behalf of European Society for Medical Oncology. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).-
dc.subject.otherCOVID-19-
dc.subject.othercancer-
dc.subject.othertreatment changes-
dc.subject.otherprognosis-
dc.subject.othersolid tumours-
dc.titleChanges in anticancer treatment plans in patients with solid cancer hospitalized with COVID-19: analysis of the nationwide BSMO-COVID registry providing lessons for the future-
dc.typeJournal Contribution-
dc.identifier.issue6-
dc.identifier.volume7-
local.bibliographicCitation.jcatA1-
local.publisher.place1043 NX AMSTERDAM, NETHERLANDS-
local.type.refereedRefereed-
local.type.specifiedArticle-
local.bibliographicCitation.artnr100610-
dc.identifier.doi10.1016/j.esmoop.2022.100610-
dc.identifier.pmid36356416-
dc.identifier.isi000903993700014-
dc.identifier.eissn2059-7029-
local.provider.typeWeb of Science-
local.uhasselt.internationalno-
item.accessRightsOpen Access-
item.contributorGeukens, T-
item.contributorBrandao, M-
item.contributorLaenen, A-
item.contributorCollignon, J-
item.contributorVan Marcke, C-
item.contributorLouviaux, I-
item.contributorDemey, W-
item.contributorVan Wambeke, S-
item.contributorSchrijvers, D-
item.contributorLecomte, S-
item.contributorMEBIS, Jeroen-
item.contributorFontaine, C-
item.contributorRutten , A-
item.contributorLybaert, W-
item.contributorAspeslagh, S-
item.contributorGoeminne, JC-
item.contributorVan Den Bulck, H-
item.contributorSeront, E-
item.contributorDe Backer, L-
item.contributorDe Roock, W-
item.contributorIgnatiadis, M-
item.contributorPrenen, H-
item.contributorVan Beckhoven, D-
item.contributorHeijlen, M-
item.contributorVerheezen, J-
item.contributorRottey, S-
item.contributorPunie, K-
item.contributorde Azambuja, E-
item.fulltextWith Fulltext-
item.fullcitationGeukens, T; Brandao, M; Laenen, A; Collignon, J; Van Marcke, C; Louviaux, I; Demey, W; Van Wambeke, S; Schrijvers, D; Lecomte, S; MEBIS, Jeroen; Fontaine, C; Rutten , A; Lybaert, W; Aspeslagh, S; Goeminne, JC; Van Den Bulck, H; Seront, E; De Backer, L; De Roock, W; Ignatiadis, M; Prenen, H; Van Beckhoven, D; Heijlen, M; Verheezen, J; Rottey, S; Punie, K & de Azambuja, E (2022) Changes in anticancer treatment plans in patients with solid cancer hospitalized with COVID-19: analysis of the nationwide BSMO-COVID registry providing lessons for the future. In: ESMO open, 7 (6) (Art N° 100610).-
crisitem.journal.issn2059-7029-
crisitem.journal.eissn2059-7029-
Appears in Collections:Research publications
Files in This Item:
File Description SizeFormat 
Changes in anticancer treatment plans in patients with solid cancer hospitalized with COVID-19_ analysis of the the future.pdfPublished version366.03 kBAdobe PDFView/Open
Show simple item record

WEB OF SCIENCETM
Citations

1
checked on Jul 13, 2024

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.